半腺低剂量率前列腺近距离放疗治疗单侧局限性前列腺癌
HAPpy试验是一项单中心IIS期试点研究,评估半腺(HG)低剂量率前列腺近距离放疗作为局灶治疗对单侧局限性前列腺癌的毒性和有效性。30例HG患者与362例全腺(WG)对照比较,植入后剂量学显示HG靶区剂量相似而尿道和肠道剂量显著降低,但两组症状评分无差异;HG组12个月尿路评分即恢复基线,性功能保留率73%对67%(P=0.84),24个月PSA降幅78%对88%(P<0.05),复发率均为3%。
要点
- HG近距离放疗靶区剂量与WG相似,尿道和肠道剂量显著降低。
- HG组12个月尿路评分恢复基线,WG组未恢复。
- 两组性功能保留率和复发率无显著差异。
核心结论
- 半腺近距离放疗的毒性和生化结局与全腺治疗大致相似,尽管半腺植入剂量更低。
研究设计与样本
- 单中心IIS期试点研究,30例半腺患者与362例全腺对照比较,对照来自前瞻性队列登记。
主要发现
- 半腺组靶区剂量与全腺组相似,尿道和肠道剂量显著降低,但植入后平均症状评分两组无差异。
- 半腺组12个月尿路评分恢复基线,全腺组未恢复。
- 性功能保留率半腺组73%、全腺组67%(P=0.84)。
- 24个月PSA降幅半腺组78%、全腺组88%(P<0.05)。
- 复发率半腺组3%(1例,55个月)、全腺组3%(9例,32-67个月)。
临床怎么用
- 半腺近距离放疗可作为单侧局限性前列腺癌的局灶治疗选择,需关注PSA降幅较低。
局限性
- 单中心试点研究,样本量小,需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To report clinical outcomes of the Hemi-Ablative Prostate Brachytherapy (HAPpy) trial evaluating treatment-related toxicity and effectiveness of hemi-gland (HG) low-dose-rate (LDR) prostate brachytherapy as a focal approach to control unilateral localised prostate cancer. PATIENTS AND METHODS: Single institution phase IIS pilot study of patients treated with focal 4D Brachytherapy™ (BXTAccelyon, Burnham, Buckinghamshire, UK). The primary outcome was patient-reported toxicity 24 months after implant. The secondary outcome was assessment of disease control. Outcomes in HG patients were compared to whole-gland (WG) controls obtained from our prospective cohort registry by negative binomial and linear regression models. RESULTS: Pre-treatment demography was similar between the 30 HG patients and 362 WG controls. Post-implant dosimetry was similar for the prostate gland target volumes and significantly reduced for the urethra and bowel in HG patients relative to WG controls, but this did not translate into a difference in post-implant mean symptom scores between the two groups. Nevertheless, the change in score from baseline indicated that the impact on pre-treatment symptom status was less after HG implants. Only HG patients showed a return to baseline urinary scores as early as 12 months. Sexual potency was conserved in 73% and 67% of HG and WG patients, respectively (P = 0.84). Post-implant prostate-specific antigen (PSA) kinetics revealed that baseline PSA was reduced at 24 months by 78% and 88% in HG and WG patients, respectively (P < 0.05). Treatment relapse occurred in one (3%) HG patient 55 months after implant and in nine (3%) WG patients at 32-67 months after implant. CONCLUSION: This pilot study suggests that treatment-related toxicity and biochemical outcomes after HG implants are broadly similar to those observed with WG treatment despite the lower dose delivered by HG implants.
引用
- Langley S, Uribe J, Uribe-Lewis S, et al. Hemi-ablative low-dose-rate prostate brachytherapy for unilateral localised prostate cancer. BJU Int. 2019. PMID: 31705700. doi:10.1111/bju.14948
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。